| Similar Articles |
|---|
 |
National Defense
November 2005
Margaret Davidson |
Biodefense Experts: Vaccines `At a Crossroads' Many of the companies seeking government funds for biodefense work are small firms with no experience in bringing a drug to market. And they face a significant challenge.   |
National Defense
June 2011
Eric Beidel |
Industry, Academia Race to Create Drugs Against Biological Warfare On the heels of anthrax comes a string of deadly agents that scientists also fear can be used as weapons and spread with ease. |
Bio-IT World
September 16, 2004
Zachary Zimmerman |
The Dark Side of Project BioShield Despite the uncertainties, an estimated 100 biopharma companies are developing anti-terror technologies. But they should examine both sides of Project BioShield before considering product development. |
National Defense
March 2005
Sandra I. Erwin |
Pentagon Redirects Priorities In Chemical-Biological Defense The Pentagon will broaden the scope of its chemical and biological defense programs, in an effort to prepare for future domestic emergencies, officials say. |
National Defense
June 2007
Breanne Wagner |
Government Contracts Focus on Vaccines, Emergency Response Since October 2006, 13 contracts have been awarded to industry and academia, ranging in value from $2.7 million to $28 million. |
National Defense
August 2005
Joe Pappalardo |
Pentagon Spurs its Biological And Chemical Defense Programs The Pentagon is trying to buttress the military's defensive posture against biological and chemical weapons by focusing on the development of advanced vaccines and improved therapeutics. A surge in money is fueling this effort. |
Bio-IT World
November 14, 2003
Jason B. Lee |
Profiting from the BioShield How can software developers ensure a share of the tremendous biodefense funding available to bio-IT companies -- and what are the risks? |
Salon.com
October 9, 2001
Suzy Hansen |
Plague fears A bioterrorism expert talks about the wicked ways of anthrax and the even deadlier potential scourge of smallpox... |
National Defense
July 2009 |
Readers Sound Off on Recent Stories 7 Deadly Myth article draws comment. |
National Defense
September 2004
Joe Pappalardo |
Security Beat Vaccine Stockpiles Now Required by Law... Commission: Military Had No Warning During 9/11... Simulated Agent Mimics Bio-Terror Weapons... Cyber-security Hampered by Lack of Attention... |
National Defense
June 2010
Grace V. Jean |
Research Challenge: How to Defend Against Still-Undefined Chemical, Biological Attacks Military scientists are often criticized for not working fast enough and for not pushing technologies into the field more expeditiously. Those working in chemical and biological sciences are no exception. |
National Defense
March 2013
Stew Magnuson |
Chemical-Biological Defense Office To Kick Off Dozens of New Programs The previous decade has seen little in terms of advancement of nuclear-radiological detection devices, and there will be a new push to update them. |
Scientific American
November 2008
John Dudley Miller |
Postal Anthrax Aftermath: Has Biodefense Spending Made Us Safer? The Anthrax attacks in 2001 led to a massive increase in biodefense funding, which critics claim has done more harm than good |
National Defense
June 2007
Stew Magnuson |
National Guard, Army Chemical Units Criticized for Being Untrained, Unprepared Acute shortages of equipment and personnel means less time, or no time, to train. |
National Defense
June 2009
Erwin & Magnuson |
7 Deadly Myths About Weapons of Terror Seven noteworthy misconceptions associated with weapons of terror. |
Salon.com
October 3, 2001
Chris Colin |
Poison on the mind Is panic the right response to the specter of bioterrorism? |
Salon.com
September 12, 2000
Arthur Allen |
The battle over bio-terror A recent report urges America to pour $13 billion into preventing disease-based warfare, but evidence suggests that our fears are misplaced. |
National Defense
March 2005
Harold Kennedy |
Homeland Defense The Defense Department's agency in charge of developing chemical and biological defense technologies is shifting its focus from large-scale incidents on the battlefield to small-scale terrorist attacks against civilians. |
Bio-IT World
April 15, 2003
James Golden |
Sequence Signatures and Homeland Security The bio-IT community has a unique opportunity to contribute to national biodefense. |
National Defense
May 2007
Wagner & Magnuson |
Expert Slams Federal Government Pandemic Plans Expert warns that mass vaccination won't work... Governors want National Guard voice at the Pentagon... U.S. food supply chain among nation's many vulnerabilities... |
Searcher
March 2002
Eva Perkins |
Bioterrorism Resources on the Internet: A Primer What is bioterrorism? Which organizations and governmental agencies publish in this area? Using the power of the beloved Internet, one can easily and quickly access a wealth of information. Here's how to do it... |
Bio-IT World
June 15, 2003
Malorye Branca |
A View to a Kill Genomics, bioinformatics, and novel laboratory techniques are converging to boost vaccine research against a new wave of emerging diseases, natural and man-made. Now, will in silico modeling ramp up sufficiently to further speed vaccine discovery? |
National Defense
November 2004
Joe Pappalardo |
Security Beat Local Responders Linked With Coast Guard Units... Russian Horror Highlights U.S. School Security... Public Would Ignore Authorities in Terror Event... Fort Detrick Begins Bio-Defense Additions... etc. |
Mother Jones
Jan/Feb 2002
Bill Hogan |
A Biodefense Boondoggle As pharmaceutical companies line up for multimillion-dollar contracts to make bioterrorism vaccines, some question whether the industry is up to the job... |
The Motley Fool
July 18, 2005
VB Rosendahl |
Profit From a Secure Homeland Project BioShield is opening up new possibilities for small biotechs. Should investors take notice? |
National Defense
August 2005
Joe Pappalardo |
Congress Poised to Act on Weak Bio-Preparedness Flaws in the U.S.' current defenses against dangerous diseases are numerous and institutional, according to experts. In response to these shortcomings, key congressional leaders are vowing action to fix the problems. |
Pharmaceutical Executive
October 1, 2014
Jill Wechsler |
Ebola Crisis Challenges Pharma R&D Companies gain support and pressure to deliver new treatments for spreading outbreak. |
American History
Margaret Davidson |
American Biowarrior A pioneer in America's biological weapons program during World War II, the unassuming Dr. Ira Baldwin was critical to the development of methods that made large-scale, safe production of the deadly toxins possible. |
Wired
September 2002
Amanda Griscom |
Take These Genes and Call Me in the Morning Gene vaccines may be relatively new, but they're the logical outgrowth of two familiar strands of medical science. |
Salon.com
October 3, 2001
Andrew Leonard |
The invisible nightmare Biological weapons are not that hard to produce, says a sober new book written before Sept. 11 -- and they're getting easier all the time... |
Fast Company
February 2002
John Ellis |
The (Life) Science of War Sun Tzu wrote "The Art of War." Now the threat of smallpox and other forms of bioterrorism has unleashed the next generation of conflict. Welcome to the science of war... |
BusinessWeek
October 24, 2005
John Carey |
New Vaccines For A Pandemic Using DNA, vast amounts of flu vaccine could be made quickly. But will the drugs work? |
Pharmaceutical Executive
July 3, 2007
Jill Wechsler |
Washington Report: Vaccines for Everyone New vaccines can be good business and a huge boon to public health. But the challenge is to establish prices that ensure global access, and to bring necessary medications to third-world countries. |
Wired
January 2003
Richard Martin |
Testing the First AIDS Vaccine Medical establishment, government, and Genentech be damned -- Don Francis has never stopped believing. Now he's about to finish testing the first human AIDS vaccine. |
Salon.com
October 27, 2000
Arthur Allen |
A cure worse than the disease? Fearing sickness and debilitation, startling numbers of American troops are refusing to take mandatory anthrax vaccinations... |
National Defense
February 2009
Magnuson & Rusling |
Senators May Seek Life Science Lab Security Regulations Life science laboratories, and similar facilities are proliferating throughout the world. Security is lax at many of them -- including the United States. Background checks for those working in the labs are spotty. |
Salon.com
October 3, 2001
Pamela Weintraub |
Be prepared? Taking precautions against bioterrorism may not be as futile as you think... |
National Defense
July 2004
Joe Pappalardo |
Scientists Seek Breakthroughs In Bio-Detection The Department of Homeland Security is seeking to upgrade its biological sensor network with more encompassing and less costly systems. |
Salon.com
December 15, 2000
Arthur Allen |
Warming to malaria With fears mounting that global climate change may cause the dreaded disease to spread, scientists turn their attention to vaccine research... |
Pharmaceutical Executive
December 1, 2005
Anthony Tao |
The Avian Few: Is it Too Late for Pharma to Re-enter the Vaccine Fray? Small profit margins and high litigation risks drove most companies out of the vaccine business decades ago. As a possible pandemic looms, pharma re-enters the fray. Is it too late? |
American Family Physician
September 1, 2003
Maurer et al. |
Smallpox Vaccine: Contraindications, Administration, and Adverse Reactions Public health departments and the U.S. military have begun the process of vaccinating soldiers and civilian first-responders. Smallpox vaccination carries some serious risks. |
American Family Physician
May 1, 2003
O'Brien & Halverson |
Recognition and Management of Bioterrorism Infections Familiarity with the infectious agents of highest priority can expedite diagnosis and initial management, and lead to a successful public health response to such an attack. |
National Defense
April 2015
Stew Magnuson |
Worldwide Biosurveillance Network Still a Distant Goal Since the anthrax attacks of 2001, the U.S. government's intention has been to create a global disease-monitoring system. |
Scientific American
July 2006
JR Minkel |
Dangling a Carrot for Vaccines Drug companies do not see much of a market in treating diseases of developing nations. Michael Kremer hopes to change that with a plan that taps the profit motive. |
The Motley Fool
May 22, 2007
Mike Havrilla |
An Emergent Opportunity The vaccine developer guided for revenue growth of 10% to 15% for this year. Emergent also has a strong balance sheet, with more than $67 million in cash and investments. Investors, take note. |
Smithsonian
November 2005
Robin Marantz Henig |
35 Who Made a Difference: D. A. Henderson Eradicating one of history's deadliest diseases was just the beginning. |
Popular Mechanics
October 16, 2006
Simon Cooper |
North Korea: The Bigger (Non-Nuclear) Threat The consensus is that North Korea has developed anthrax, plague and botulism toxin as weapons, and has extensively researched at least six other germs including smallpox and typhoid. |
Pharmaceutical Executive
February 1, 2009
Joanna Breitstein |
Vaccines for All The world is suffering. But just over the horizon is a new access equation that could speed innovative vaccines to where they're needed most. |
Popular Mechanics
February 2007
Simon Cooper |
North Korea's Biochemical Threat While its nuclear test spurs outrage, North Korea grows a vast biochemical weapons arsenal in secrecy. We investigate Kim Jong Il's deception, his country's human trials and the terror potential of this rogue nation's deadly harvest. |
Pharmaceutical Executive
July 10, 2014
Fitzpatrick & Mohan |
Vaccines: Fire in the Cold Chain It's only recently that vaccine producers experienced the commercial returns commensurate with vaccines: long record of positive public health performance. |
